Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorMITCHELL, P.
dc.contributor.authorRODRÍGUEZ, F. J.
dc.contributor.authorJOUSSEN, A. M.
dc.contributor.authorKOH, A.
dc.contributor.authorETER, N.
dc.contributor.authorWONG, D. T.
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorKOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535
IDREF: 028739272
dc.contributor.authorOKADA, A. A.
dc.date.accessioned2021-03-09T14:33:06Z
dc.date.available2021-03-09T14:33:06Z
dc.date.issued2020-12-16
dc.identifier.issn0275-004xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/26469
dc.description.abstractEnPURPOSE: This article aims to review current evidence on the development, diagnosis, and management of retinal pigment epithelium (RPE) tear during anti-vascular endothelial growth factor (VEGF) therapy. METHODS: Literature searches were performed using MEDLINE/PubMed databases (cut-off date: August 2019). RESULTS: Three key recommendations were made based on existing literature and clinical experience. Multimodal imaging with color fundus photography, optical coherence tomography (OCT), near-infrared reflectance imaging, fundus autofluorescence imaging, OCT-angiography and/or fluorescein angiography are recommended to diagnose RPE tear and assess risk factors. RPE tears can be graded by size and foveal involvement. Patients at high risk of developing RPE tear should be monitored following each anti-VEGF injection. If risk factors worsen, it is not yet definitively known whether anti-VEGF administration should be more frequent, or alternatively stopped in such patients. Prospective research into high-risk characteristics is needed. After RPE tear develops, anti-VEGF treatment should be continued in patients with active disease (as indicated by presence of intra- or subretinal fluid), although cessation of therapy should be considered in eyes with multilobular tears. CONCLUSION: While evidence to support the assumption that anti-VEGF treatment contributes to development of RPE tear is not definitive, some data suggest this link.
dc.language.isoENen_US
dc.title.enManagement of retinal pigment epithelium tear during anti-VEGF therapy
dc.title.alternativeRetinaen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1097/iae.0000000000003083en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed33346626en_US
bordeaux.journalRETINAen_US
bordeaux.volumePublish Ahead of Printen_US
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - U1219en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.teamLEHA_BPH
bordeaux.teamLEHA_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03163949
hal.version1
hal.date.transferred2021-03-09T14:33:13Z
hal.exporttrue
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=RETINA&rft.date=2020-12-16&rft.volume=Publish%20Ahead%20of%20Print&rft.eissn=0275-004x&rft.issn=0275-004x&rft.au=MITCHELL,%20P.&RODR%C3%8DGUEZ,%20F.%20J.&JOUSSEN,%20A.%20M.&KOH,%20A.&ETER,%20N.&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée